Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery
CA 2423595 C · Owner: Silver, David M. · Inventors: Tozser, Jozsef; Silver, David M.; Berta, Andras
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a method to prevent or reduce postoperative corneal subepithelial haze after excimer laser photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK) surgery. According to the method, a therapeutically effective amount of one or more plasminogen activators, most preferably urokinase (uPA) is administered topically to the , surface of the affected eye at levels between 0.1 and 2,500 IU/ml about eight , to twelve times on the day of surgery and four to eight times per day for , about the next six to twelve days thereafter. The most preferred therapeutic amount is from about 0.1-1 IU uPA/ml, and also 1-10 IU/ml. Plasminogen activators …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 12, 2001 and granted January 8, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 12, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 12, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.